Edge Rewrite
restyle Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

5C-D

Add links
From Wikipedia, the free encyclopedia

5C-D
Clinical data
Other names4-Methyl-2,5-dimethoxy-α-propylphenethylamine; 2,5-Dimethoxy-4-methyl-α-propylphenethylamine; α-Propyl-Ariadne; 5C-DOM; α-Propyl-2C-D
Drug classSerotonin 5-HT2 receptor agonist
ATC code
  • None
Identifiers
  • 1-(2,5-dimethoxy-4-methylphenyl)pentan-2-amine
CAS Number
PubChem CID
Chemical and physical data
FormulaC14H23NO2
Molar mass237.343 g·mol−1
3D model (JSmol)
  • CCCC(CC1=C(C=C(C(=C1)OC)C)OC)N
  • InChI=1S/C14H23NO2/c1-5-6-12(15)8-11-9-13(16-3)10(2)7-14(11)17-4/h7,9,12H,5-6,8,15H2,1-4H3
  • Key:VZEDHPXICDLLDV-UHFFFAOYSA-N

5C-D, also known as 4-methyl-2,5-dimethoxy-α-propylphenethylamine, is a putatively non-hallucinogenic serotonin 5-HT2 receptor agonist of the phenethylamine and α-propylphenethylamine families related to the 4C drug Ariadne (4C-D).[1][2]

At the serotonin 5-HT2A receptor, 5C-D is a potent and higher-efficacy partial agonist, with an EC50Tooltip half-maximal effective concentration of 291 nM and an EmaxTooltip maximal efficacy of 69%.[1][2] It is about half as potent as Ariadne as a serotonin 5-HT2A receptor agonist and has about 15% lower efficacy in activating the receptor in comparison.[1][2] 5C-D has also been shown to be a serotonin 5-HT2B receptor agonist.[2] In contrast to Ariadne and serotonergic psychedelics, 5C-D does not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.[2]

5C-D was first described in the scientific literature by Michael Cunningham and colleagues by 2023.[2] It was synthesized and assessed during structure–activity relationship (SAR) studies of Ariadne.[1][2]

See also

[edit]

References

[edit]
  1. 1 2 3 4 Duan W, Cao D, Wang S, Cheng J (January 2024). "Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants". Chemical Reviews. 124 (1): 124–163. doi:10.1021/acs.chemrev.3c00375. PMID 38033123. As mentioned earlier, the potency and efficacy would be weakened if the methyl group on the α-position of DOM (EC50 = 36.9 nM, Emax = 96.6%) is replaced with an ethyl group (95, ariadne, EC50 = 182 nM, Emax = 79.1%) in the Gq-dissociation BRET assay, and further reduced with an n-propyl group (137, 5C-D, EC50 = 291 nM, Emax = 68.8%).173 These results demonstrated that the length of the alkyl substituent at this position is related to compound activity at the 5-HT2AR.
  2. 1 2 3 4 5 6 7 Cunningham MJ, Bock HA, Serrano IC, Bechand B, Vidyadhara DJ, Bonniwell EM, et al. (January 2023). "Pharmacological Mechanism of the Non-hallucinogenic 5-HT2A Agonist Ariadne and Analogs". ACS Chemical Neuroscience. 14 (1): 119–135. doi:10.1021/acschemneuro.2c00597. PMC 10147382. PMID 36521179. Furthermore, the α-propyl analog (compound 5C-D) showed an additional decrease in potency (∼2-fold) and efficacy (∼15 % drop) relative to Ariadne (Figure 3D). [...] Also, α-propyl-Ariadne (5C-D) induced HTR response that is indistinguishable from vehicle (Figure S13). [...]
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=5C-D&oldid=1366603933"